Search results
AstraZeneca admits its Covid vaccine can cause rare side effect in court documents for first time
The Telegraph via Yahoo News· 6 days agoAstraZeneca has admitted for the first time in court documents that its Covid vaccine can cause a...
AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very ...
Benzinga via Yahoo Finance· 5 days agoEuropean pharma giant AstraZeneca Plc’s (NASDAQ:AZN) Covid vaccine, developed with the University of...
Covishield: Parents File Lawsuit Against Serum Institute Amid AstraZeneca’s Report| Oneindia
Homenewshere.com· 3 days agoAfter AstraZeneca's acknowledgment of rare side effects, parents of a woman allegedly deceased...
Fmr. Biden Admin officials testify on pressuring Big Tech to censor pandemic posts
WJLA· 3 days agoOn Wednesday, former Biden Administration officials were summoned to Capitol Hill to testify in a...
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Morningstar· 4 days agoAmgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego. "We look ...
Earnings call: Daiichi Sankyo posts strong FY 2023 results, plans growth
Investing.com· 6 days agoThe pharmaceutical company's strong performance was primarily driven by robust sales of its key...
A Better Concept For mRNA Vaccines: Self-Amplification
Forbes· 6 days agoTwo new self-amplifying mRNA vaccines herald a new era of vaccination for coronaviruses.
Covaxin has excellent safety record, says Bharat Biotech
Investing.com· 3 days agoCovaxin has excellent safety record, says Bharat Biotech
Biotech’s bind over China bill
Politico· 2 days agoCEO Stéphane Bancel touted the vaccine candidate’s safety and efficacy data as “stronger” than competitors’ though another company official noted Moderna ...
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant...
Benzinga· 3 days agoBeyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease